POMPANO BEACH, FL / October 18, 2023 / BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to be held from October 24th - 27th.
Jason Matuszewski, Chief Executive Officer of BioStem, said, "BioStem has achieved a number of significant milestones in 2023, including the strategic acquisition of Auxocell Laboratories' assets and securing an agreement with NovaBay Pharmaceuticals to commercialize our amniotic tissue allograft under the Avenova® Allograft brand for ocular surface repair. With our newly formed partnership with Lovell® Government Services, we are also pleased to have been listed on key government contract vehicles for the Department of Defense and the Department of Veteran Affairs.
"In September 2023, we announced the nationwide launch of AmnioWrap2TM in collaboration with leading US wound market solutions provider, Venture Medical, LLC. The same month we received Independent Review Board approval for a clinical study evaluating our Vendaje product for Diabetic Foot Ulcers (DFU) and we expect to initiate this study before year-end.
"My colleagues and I look forward to sharing these numerous achievements, how they are positioning us for success, and our forward-looking strategy to continue our growth trajectory into 2024 and beyond with investors at the MicroCap Rodeo," said Mr. Matuszewski.
The presentation will begin at 9:00 ET on Wednesday, October 25. To register to attend and access the presentation, please visit https://www.webcaster4.com/Webcast/Page/2995/49249.
